Combination Therapy of Cisplatin and other Agents for Osteosarcoma: A Review

Author(s): Mohamad Z. Kasiram, Hermizi Hapidin*, Hasmah Abdullah, Azlina Ahmad, Sarina Sulong

Journal Name: Current Cancer Therapy Reviews

Volume 17 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: Osteosarcoma is the most common type of primary bone tumor in children and adolescents, which is associated with rapid progression and poor prognosis. Multimodal therapy is the most common approach utilized for osteosarcoma management, such as the application of chemotherapy in combination with surgery or radiation therapy. Cisplatin is one of the predominantly used chemotherapeutic agents for osteosarcoma. Optimally, it is employed in combination with other chemotherapeutic drugs along with surgery or radiation therapy. Despite the availability of numerous treatment approaches, the patient survival rate has not definitively improved over the past three decades.

Methods: We have summarized all findings regarding the combination of cisplatin with other chemotherapeutic agents as well as with phytochemical compounds.

Results: A combination of cisplatin with a phytochemical compound synergistically enhances the killing effect of cisplatin on osteosarcoma cells with fewer side effects compared to combination with other chemotherapeutic agents.

Conclusion: Conclusively, a combination of cisplatin with selected chemotherapeutic drugs has been shown to be effective. However, the unchanged survival rate has posed an urge to search for a new combination regimen. As a collaborative effort to substantiate the therapeutic efficacy, the combination with phytochemical compounds shows a promising response both in vitro as well as in the preclinical study.

Keywords: Osteosarcoma, chemotherapy, combination treatment, cisplatin, phytochemical compound, natural product.

[1]
Jaffe N. Osteosarcoma. Pediatrics Rev 1991; 12(11): 333-4.
[PMID: 2062744]
[2]
Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: Data from the surveillance, epidemiology, and end results program. Cancer 2009; 115(7): 1531-43.
[http://dx.doi.org/10.1002/cncr.24121] [PMID: 19197972]
[3]
Spector LG, Ritter K, Demerath EW, et al. Abstract 2532: Pediatric osteosarcoma patients are taller than average from birth to age twelve: A report from the Children’s Oncology Group. Cancer Res 2013; 73(8): 2532.
[4]
Cheng M, Huang W, Cai W, et al. Growth hormone receptor promotes osteosarcoma cell growth and metastases. FEBS Open Bio 2020; 10(1): 127-34.
[http://dx.doi.org/10.1002/2211-5463.12761] [PMID: 31725956]
[5]
Domínguez-Malagón HR, González-Conde E, Cano-Valdez AM, Luna-Ortiz K, Mosqueda-Taylor A. Expression of hormonal receptors in osteosarcomas of the jaw bones: Clinico-pathological analysis of 21 cases. Med Oral Patol Oral Cir Bucal 2014; 19(1): e44-8.
[http://dx.doi.org/10.4317/medoral.18729] [PMID: 24121902]
[6]
Walker MJ, Chaudhuri PK, Beattie CW, Das Gupta TK. Steroid receptors in malignant skeletal tumors. Cancer 1980; 45(12): 3004-7.
[http://dx.doi.org/10.1002/1097-0142(19800615)45:12<3004::AID-CNCR2820451221>3.0.CO;2-P] [PMID: 6930316]
[7]
Laurent M, Antonio L, Sinnesael M, et al. Androgens and estrogens in skeletal sexual dimorphism. Asian J Androl 2014; 16(2): 213-22.
[http://dx.doi.org/10.4103/1008-682X.122356] [PMID: 24385015]
[8]
Wang W, Yang J, Wang Y, et al. Survival and prognostic factors in Chinese patients with osteosarcoma: 13-year experience in 365 patients treated at a single institution. Pathol Res Pract 2017; 213(2): 119-25.
[http://dx.doi.org/10.1016/j.prp.2016.11.009] [PMID: 28040328]
[9]
Nie Z, Peng H. Osteosarcoma in patients below 25 years of age: An observational study of incidence, metastasis, treatment and outcomes. Oncol Lett 2018; 16(5): 6502-14.
[http://dx.doi.org/10.3892/ol.2018.9453] [PMID: 30405789]
[10]
Broadhead ML, Clark JCM, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: A review. Sarcoma 2011; 2011: 959248.
[http://dx.doi.org/10.1155/2011/959248] [PMID: 21559216]
[11]
Durfee RA, Mohammed M, Luu HH. Review of osteosarcoma and current management. Rheumatol Ther 2016; 3(2): 221-43.
[http://dx.doi.org/10.1007/s40744-016-0046-y] [PMID: 27761754]
[12]
Longhi A, Errani C, De Paolis M, Mercuri M, Bacci G. Primary bone osteosarcoma in the pediatric age: State of the art. Cancer Treat Rev 2006; 32(6): 423-36.
[http://dx.doi.org/10.1016/j.ctrv.2006.05.005] [PMID: 16860938]
[13]
Lamplot JD, Denduluri S, Qin J, et al. The current and future therapies for human osteosarcoma. Curr Cancer Ther Rev 2013; 9(1): 55-77.
[http://dx.doi.org/10.2174/1573394711309010006] [PMID: 26834515]
[14]
Picci P. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007; 2(1): 6.
[http://dx.doi.org/10.1186/1750-1172-2-6] [PMID: 17244349]
[15]
Ferrari S, Palmerini E, Staals EL, et al. The treatment of nonmetastatic high grade osteosarcoma of the extremity: Review of the Italian Rizzoli experience. Impact on the future.Pediatric and adolescent osteosarcoma. Cancer treatment and research. Boston, MA: Springer 2009; pp. 275-87.
[http://dx.doi.org/10.1007/978-1-4419-0284-9_14]
[16]
Lindsey BA, Markel JE, Kleinerman ES. Osteosarcoma overview. Rheumatol Ther 2017; 4(1): 25-43.
[http://dx.doi.org/10.1007/s40744-016-0050-2] [PMID: 27933467]
[17]
San-Julian M, Diaz-de-Rada P, Noain E, Sierrasesumaga L. Bone metastases from osteosarcoma. Int Orthop 2003; 27(2): 117-20.
[http://dx.doi.org/10.1007/s00264-002-0407-8] [PMID: 12700938]
[18]
Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9(4): 422-41.
[http://dx.doi.org/10.1634/theoncologist.9-4-422] [PMID: 15266096]
[19]
Chou AJ, Geller DS, Gorlick R. Therapy for osteosarcoma: Where do we go from here? Paediatr Drugs 2008; 10(5): 315-27.
[http://dx.doi.org/10.2165/00148581-200810050-00005] [PMID: 18754698]
[20]
Bacci G, Longhi A, Bertoni F, et al. Bone metastases in osteosarcoma patients treated with neoadjuvant or adjuvant chemotherapy: The Rizzoli experience in 52 patients. Acta Orthop 2006; 77(6): 938-43.
[http://dx.doi.org/10.1080/17453670610013268] [PMID: 17260205]
[21]
Doval DC, Chacko M, Sinha R, et al. A rare case of brain metastasis in a patient with osteosarcoma. South Asian J Cancer 2017; 6(1): 36-7.
[http://dx.doi.org/10.4103/2278-330X.202572] [PMID: 28413797]
[22]
Shweikeh F, Bukavina L, Saeed K, et al. Brain metastasis in bone and soft tissue cancers: A review of incidence, interventions, and outcomes. Sarcoma 2014; 2014: 475175.
[http://dx.doi.org/10.1155/2014/475175] [PMID: 24757391]
[23]
Sun F, Zhang Y, Xu L, et al. Proteasome inhibitor mg132 enhances cisplatin-induced apoptosis in osteosarcoma cells and inhibits tumor growth. Oncol Res 2018; 26(4): 655-64.
[http://dx.doi.org/10.3727/096504017X15119525209765] [PMID: 29191257]
[24]
Li C, Cai J, Ge F, Wang G. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma. Int J Mol Med 2018; 42(4): 1799-808.
[http://dx.doi.org/10.3892/ijmm.2018.3753] [PMID: 30015899]
[25]
Yu L, Fan Z, Fang S, et al. Cisplatin selects for stem-like cells in osteosarcoma by activating Notch signaling. Oncotarget 2016; 7(22): 33055-68.
[http://dx.doi.org/10.18632/oncotarget.8849] [PMID: 27102300]
[26]
Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31(15): 1869-83.
[http://dx.doi.org/10.1038/onc.2011.384] [PMID: 21892204]
[27]
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol 2014; 740: 364-78.
[http://dx.doi.org/10.1016/j.ejphar.2014.07.025] [PMID: 25058905]
[28]
Mohanty S, Aghighi M, Yerneni K, Theruvath JL, Daldrup-Link HE. Improving the efficacy of osteosarcoma therapy: Combining drugs that turn cancer cell ‘don’t eat me’ signals off and ‘eat me’ signals on. Mol Oncol 2019; 13(10): 2049-61.
[http://dx.doi.org/10.1002/1878-0261.12556] [PMID: 31376208]
[29]
Wang Y, Teng JS. Increased multi-drug resistance and reduced apoptosis in osteosarcoma side population cells are crucial factors for tumor recurrence. Exp Ther Med 2016; 12(1): 81-6.
[http://dx.doi.org/10.3892/etm.2016.3303] [PMID: 27347020]
[30]
Brady SW, Ma X, Bahrami A, et al. The clonal evolution of metastatic osteosarcoma as shaped by cisplatin treatment. Mol Cancer Res 2019; 17(4): 895-906.
[http://dx.doi.org/10.1158/1541-7786.MCR-18-0620] [PMID: 30651371]
[31]
Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database. Cancer Epidemiol 2015; 39(4): 593-9.
[http://dx.doi.org/10.1016/j.canep.2015.05.001] [PMID: 26002013]
[32]
Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. Expert Rev Anticancer Ther 2018; 18(1): 39-50.
[http://dx.doi.org/10.1080/14737140.2018.1413939] [PMID: 29210294]
[33]
Malanchi I, Santamaria-Martínez A, Susanto E, et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2011; 481(7379): 85-9.
[http://dx.doi.org/10.1038/nature10694] [PMID: 22158103]
[34]
Jaffe N. Historical perspective on the introduction and use of chemotherapy for the treatment of osteosarcoma. Current advances in osteosarcoma Advances in experimental medicine and biology. Switzerland: Springer 2014; pp. 1-30.
[http://dx.doi.org/10.1007/978-3-319-04843-7_1]
[35]
Dear RF, McGeechan K, Jenkins MC, Barratt A, Tattersall MH, Wilcken N. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2013; 2013: 12.
[http://dx.doi.org/10.1002/14651858.CD008792.pub2]
[36]
Saputra EC, Huang L, Chen Y, Tucker-Kellogg L. Combination therapy and the evolution of resistance: The theoretical merits of synergism and antagonism in cancer. Cancer Res 2018; 78(9): 2419-31.
[http://dx.doi.org/10.1158/0008-5472.CAN-17-1201] [PMID: 29686021]
[37]
Hou M, Huang Z, Chen S, et al. Synergistic antitumor effect of suberoylanilide hydroxamic acid and cisplatin in osteosarcoma cells. Oncol Lett 2018; 16(4): 4663-70.
[http://dx.doi.org/10.3892/ol.2018.9224] [PMID: 30197679]
[38]
Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci USA 2013; 110(2): E170-9.
[http://dx.doi.org/10.1073/pnas.1210419110] [PMID: 23251029]
[39]
Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: An overview. Cancers (Basel) 2014; 6(3): 1769-92.
[http://dx.doi.org/10.3390/cancers6031769] [PMID: 25198391]
[40]
Moscow J, Morrow CS, Cowan KH. General mechanisms of drug resistance. Kufe DW, Pollock RE WR, Eds. Cancer Medicine 6th edition. Holland-Frei: Hamilton (ON): BC Decker 2003.
[41]
He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma (Review). Oncol Lett 2014; 7(5): 1352-62.
[http://dx.doi.org/10.3892/ol.2014.1935] [PMID: 24765137]
[42]
Palmer AC, Sorger PK. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell 2017; 171(7): 1678-1691.e13.
[http://dx.doi.org/10.1016/j.cell.2017.11.009] [PMID: 29245013]
[43]
Daughton CG, Ruhoy IS. Lower-dose prescribing: Minimizing “side effects” of pharmaceuticals on society and the environment. Sci Total Environ 2013; 443: 324-37.
[http://dx.doi.org/10.1016/j.scitotenv.2012.10.092] [PMID: 23201698]
[44]
Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop 2006; 30(6): 445-51.
[http://dx.doi.org/10.1007/s00264-006-0192-x] [PMID: 16896870]
[45]
Rastogi S, Aggarwal A, Tiwari A, Sharma V. Chemotherapy in nonmetastatic osteosarcoma: Recent advances and implications for developing countries. J Glob Oncol 2018; 4: 1-5.
[http://dx.doi.org/10.1200/JGO.2016.007336] [PMID: 30241154]
[46]
Isakoff MS, Bielack SS, Meltzer P, Gorlick R. Osteosarcoma: Current treatment and a collaborative pathway to success. J Clin Oncol 2015; 33(27): 3029-35.
[http://dx.doi.org/10.1200/JCO.2014.59.4895] [PMID: 26304877]
[47]
Whelan JS, Davis LE. Osteosarcoma, Chondrosarcoma, and Chordoma. J Clin Oncol 2018; 36(2): 188-93.
[http://dx.doi.org/10.1200/JCO.2017.75.1743] [PMID: 29220289]
[48]
Iwata S, Ishii T, Kawai A, et al. Prognostic factors in elderly osteosarcoma patients: A multi-institutional retrospective study of 86 cases. Ann Surg Oncol 2014; 21(1): 263-8.
[http://dx.doi.org/10.1245/s10434-013-3210-4] [PMID: 23975321]
[49]
Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20(3): 776-90.
[http://dx.doi.org/10.1200/JCO.2002.20.3.776] [PMID: 11821461]
[50]
Collier CD, Wirtz EC, Knafler GJ, Morris WZ, Getty PJ, Greenfield EM. Micrometastatic drug screening platform shows heterogeneous response to MAP chemotherapy in osteosarcoma cell lines. Clin Orthop Relat Res 2018; 476(7): 1400-11.
[http://dx.doi.org/10.1007/s11999.0000000000000059] [PMID: 29481344]
[51]
Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004; 100(10): 2222-32.
[http://dx.doi.org/10.1002/cncr.20255] [PMID: 15139068]
[52]
Xu M, Xu SF, Yu XC. Clinical analysis of osteosarcoma patients treated with high-dose methotrexate-free neoadjuvant chemotherapy. Curr Oncol 21(21)(5): 678.
[http://dx.doi.org/10.3747/co.21.1973]
[53]
Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 2012; 73(1): 106-14.
[http://dx.doi.org/10.1111/j.1365-2125.2011.04054.x] [PMID: 21707700]
[54]
National Comprehensive Cancer Network (NCCN) 2020. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx#bone
[55]
Le Deley M-C, Guinebretière J-M, Gentet J-C, et al. Société Française d’Oncologie Pédiatrique (SFOP). SFOP OS94: A randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer 2007; 43(4): 752-61.
[http://dx.doi.org/10.1016/j.ejca.2006.10.023] [PMID: 17267204]
[56]
Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: The first study of the European Osteosarcoma Intergroup. J Clin Oncol 1992; 10(10): 1579-91.
[http://dx.doi.org/10.1200/JCO.1992.10.10.1579] [PMID: 1403038]
[57]
Bacci G, Ferrari S, Longhi A, et al. Italian Sarcoma Group/Scandinavian Sarcoma Group. High dose ifosfamide in combination with high dose methotrexate, adriamycin and cisplatin in the neoadjuvant treatment of extremity osteosarcoma: Preliminary results of an Italian Sarcoma Group/Scandinavian Sarcoma Group pilot study. J Chemother 2002; 14(2): 198-206.
[http://dx.doi.org/10.1179/joc.2002.14.2.198] [PMID: 12017378]
[58]
Ferrari S, Smeland S, Mercuri M, et al. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23(34): 8845-52.
[http://dx.doi.org/10.1200/JCO.2004.00.5785] [PMID: 16246977]
[59]
Yu D, Zhang S, Feng A, et al. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation. Medicine (Baltimore) 2019; 98(19): e15582.
[http://dx.doi.org/10.1097/MD.0000000000015582] [PMID: 31083238]
[60]
Wang X, Zheng H, Shou T, Tang C, Miao K, Wang P. Effectiveness of multi-drug regimen chemotherapy treatment in osteosarcoma patients: A network meta-analysis of randomized controlled trials. J Orthop Surg Res 2017; 12(1): 52.
[http://dx.doi.org/10.1186/s13018-017-0544-9] [PMID: 28356114]
[61]
Anderson P. Chemotherapy for osteosarcoma with high-dose methotrexate is effective and outpatient therapy is now possible. Nat Clin Pract Oncol 2007; 4(11): 624-5.
[http://dx.doi.org/10.1038/ncponc0953] [PMID: 17876353]
[62]
Kleinerman E. Maximum benefit of chemotherapy for osteosarcoma achieved-what are the next steps? Lancet Oncol 2016; 17(10): 1340-2.
[http://dx.doi.org/10.1016/S1470-2045(16)30270-4] [PMID: 27569441]
[63]
Taran SJ, Taran R, Malipatil NB. Pediatric osteosarcoma: An updated review. Indian J Med Paediatr Oncol 2017; 38(1): 33-43.
[http://dx.doi.org/10.4103/0971-5851.203513] [PMID: 28469335]
[64]
Bacci G, Picci P, Ferrari S, et al. Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin. Cancer 1993; 72(11): 3227-38.
[http://dx.doi.org/10.1002/1097-0142(19931201)72:11<3227::AID-CNCR2820721116>3.0.CO;2-C] [PMID: 8242546]
[65]
Jaffe N, Patel SR, Benjamin RS. Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Hematol Oncol Clin North Am 1995; 9(4): 825-40.
[http://dx.doi.org/10.1016/S0889-8588(18)30074-1] [PMID: 7490244]
[66]
Zinser JW, Castañeda N, Alfeirán A, et al. Treatment of osteosarcoma with cisplatin and doxorubicin either as adjuvant or neo-adjuvant chemotherapy. Cancer Treat An Update 1994; pp. 565-7.
[http://dx.doi.org/10.1007/978-2-8178-0765-2_120]
[67]
Lewis I, Nooij M, Whelan J, et al. Chemotherapy at standard or increased dose intensity in patients with operable osteosarcoma of the extremity: A randomised controlled trial of the European Osteosarcoma Intergroup (ISRCTN 86294690). SIOP, Cairo. 2003.
[68]
Jaffe N. Osteosarcoma: Review of the past, impact on the future. The American experience.Pediatric and adolescent osteosarcoma cancer treatment and research. Boston, MA: Springer 2009; pp. 239-62.
[http://dx.doi.org/10.1007/978-1-4419-0284-9_12]
[69]
Baum E, Greenberg L, Gaynon P, Krivit W, Hammond D. USE of cis-platinum diammine dichloride (CPDD) in osteogenic-sarcoma (OS) IN children. Proc Am Associat Cancer Res 1978; 19: 385-95.
[70]
Nitschke R, Starling KA, Vats T, Bryan H. Cis-diamminedichloroplatinum (NSC-119875) in childhood malignancies: A southwest oncology group study. Med Pediatr Oncol 1978; 4(2): 127-32.
[http://dx.doi.org/10.1002/mpo.2950040208] [PMID: 275532]
[71]
Ochs JJ, Freeman AI, Douglass HO Jr, Higby DS, Mindell ER, Sinks LF. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. Cancer Treat Rep 1978; 62(2): 239-45.
[PMID: 346212]
[72]
Benjamin RS, Chawla SP, Carrasco CH, et al. Primary chemotherapy for osteosarcoma with systemic adriamycin and intra-arterial cisplatin. Cancer Bull 1990; 40(2): 314-7.
[73]
Sirichativapee W, Wisanuyotin T, Pattanittum P, et al. Chemotherapy for treating high-grade osteosarcoma in children and young adults. Cochrane Database Syst Rev 2018; 2018(5): CD012372.
[http://dx.doi.org/10.1002/14651858.CD012372]
[74]
Ornadel D, Souhami RL, Whelan J, et al. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: Phase II trial of the European Osteosarcoma Intergroup. J Clin Oncol 1994; 12(9): 1842-8.
[http://dx.doi.org/10.1200/JCO.1994.12.9.1842] [PMID: 7521906]
[75]
Voûte PA, Souhami RL, Nooij M, et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). Ann Oncol 1999; 10(10): 1211-8.
[http://dx.doi.org/10.1023/A:1008361612767] [PMID: 10586339]
[76]
Harris MB, Cantor AB, Goorin AM, et al. Treatment of osteosarcoma with ifosfamide: Comparison of response in pediatric patients with recurrent disease versus patients previously untreated: A Pediatric Oncology Group study. Med Pediatr Oncol 1995; 24(2): 87-92.
[http://dx.doi.org/10.1002/mpo.2950240205] [PMID: 7990769]
[77]
Basaran M, Bavbek ES, Saglam S, et al. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastatic and extremity osteosarcomas. Oncology 2007; 72(3-4): 255-60.
[http://dx.doi.org/10.1159/000113017] [PMID: 18185020]
[78]
Navid F, Santana VM, Billups CA, et al. Concomitant administration of vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for high-risk sarcomas: The St. Jude Children’s Research Hospital experience. Cancer 2006; 106(8): 1846-56.
[http://dx.doi.org/10.1002/cncr.21810] [PMID: 16541446]
[79]
Craft AW, Burgers JMV. The European Osteosarcoma Intergroup. (E.O.I.) studies 1980–1991.Osteosarcoma in adolescents and young adults: New developments and controversies. Boston, MA: Springer 1993; pp. 279-86.
[http://dx.doi.org/10.1007/978-1-4615-3518-8_33]
[80]
Pratt CB, Meyer WH, Rao BN, Parham DM, Fleming ID. Osteosarcoma studies at St. Jude Children’s Research Hospital from 1968 through 1990. Humphrey GB, Koops HS, Molenaar WM, Postma A, Eds Osteosarcoma in adolescents and young adults: New developments and controversies. Boston MA: Springer 1990; pp. 323-6.
[81]
Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6(2): 329-37.
[http://dx.doi.org/10.1200/JCO.1988.6.2.329] [PMID: 2448428]
[82]
Stöhr W, Langer T, Kremers A, et al. German late effects working group in the german society of pediatric oncology and hematology. Cisplatin-induced ototoxicity in osteosarcoma patients: A report from the late effects surveillance system. Cancer Invest 2005; 23(3): 201-7.
[http://dx.doi.org/10.1081/CNV-200055951] [PMID: 15945505]
[83]
Zhang Y, Yang J, Zhao N, et al. Progress in the chemotherapeutic treatment of osteosarcoma. Oncol Lett 2018; 16(5): 6228-37.
[http://dx.doi.org/10.3892/ol.2018.9434] [PMID: 30405759]
[84]
Doz F, Pinkerton R. What is the place of carboplatin in paediatric oncology? Eur J Cancer 1994; 30A(2): 194-201.
[http://dx.doi.org/10.1016/0959-8049(94)90086-8] [PMID: 8155394]
[85]
Robson H, Meyer S, Shalet SM, Anderson E, Roberts S, Eden OB. Platinum agents in the treatment of osteosarcoma: Efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines. Med Pediatr Oncol 2002; 39(6): 573-80.
[http://dx.doi.org/10.1002/mpo.10076] [PMID: 12376980]
[86]
Nitz A, Kontopantelis E, Bielack S, et al. Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett 2013; 5(1): 311-5.
[http://dx.doi.org/10.3892/ol.2012.997] [PMID: 23255940]
[87]
Jin W, Cai L, Niu G, Tao H. Proliferation inhibition effect of docetaxel combined with cisplatin on osteosarcoma cells. Med Oncol 2010; 27(2): 491-4.
[http://dx.doi.org/10.1007/s12032-009-9240-x] [PMID: 19488863]
[88]
Tao H, Tang X, Jin L, et al. Synergistic effect of docetaxel combined with cisplatin on inhibiting human osteosarcoma in nude mice. Biochem Biophys Res Commun 2018; 505(2): 372-7.
[http://dx.doi.org/10.1016/j.bbrc.2018.09.105] [PMID: 30253943]
[89]
Yu W-X, Tang L-N, Lin F, Yao Y, Shen Z. Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: Clinical outcomes from a retrospective database monitored in a single institute. Oncol Lett 2014; 8(5): 2243-8.
[http://dx.doi.org/10.3892/ol.2014.2472] [PMID: 25289103]
[90]
Mangla B, Kohli K. Combination of natural agent with synthetic drug for the breast cancer therapy. Int J Drug Dev Res 2018; 10(1): 22-6.
[91]
Aung TN, Qu Z, Kortschak RD, Adelson DL. Understanding the effectiveness of natural compound mixtures in cancer through their molecular mode of action. Int J Mol Sci 2017; 18(3): 656.
[http://dx.doi.org/10.3390/ijms18030656] [PMID: 28304343]
[92]
Sebastian KS, Thampan RV. Differential effects of soybean and fenugreek extracts on the growth of MCF-7 cells. Chem Biol Interact 2007; 170(2): 135-43.
[http://dx.doi.org/10.1016/j.cbi.2007.07.011] [PMID: 17850779]
[93]
Cragg GM, Newman DJ. Natural product drug discovery in the next millennium. Pharm Biol 2001; 39(Suppl. 1): 8-17.
[http://dx.doi.org/10.1076/phbi.39.7.8.5868] [PMID: 21554167]
[94]
Nowak R, Olech M, Nowacka N. Plant polyphenols as chemopreventive agents. In: Watson RR, Preedy VR, Zibadi S, Eds. Polyphenols in human health and disease. Academic Press 2014; pp. 1289-307.
[http://dx.doi.org/10.1016/B978-0-12-398456-2.00086-4]
[95]
Peng L, Liu A, Shen Y, et al. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-κB pathway. Oncol Rep 2013; 29(2): 571-8.
[http://dx.doi.org/10.3892/or.2012.2165] [PMID: 23232982]
[96]
Chen K-H, Chen C-H, Wallace CG, et al. Intravenous administration of xenogenic adipose-derived mesenchymal stem cells (ADMSC) and ADMSC-derived exosomes markedly reduced brain infarct volume and preserved neurological function in rat after acute ischemic stroke. Oncotarget 2016; 7(46): 74537-56.
[http://dx.doi.org/10.18632/oncotarget.12902] [PMID: 27793019]
[97]
Budisan L, Gulei D, Zanoaga OM, et al. Dietary intervention by phytochemicals and their role in modulating coding and non-coding genes in cancer. Int J Mol Sci 2017; 18(6): E1178.
[http://dx.doi.org/10.3390/ijms18061178] [PMID: 28587155]
[98]
Albulescu M. Phytochemicals in antitumor herbs and herbal formulas. Phytochemicals - isolation, characterisation and role in human health. In Tech 2015; p. 45.
[http://dx.doi.org/10.5772/60422]
[99]
Tomeh MA, Hadianamrei R, Zhao X. A review of curcumin and its derivatives as anticancer agents. Int J Mol Sci 2019; 20(5): 1033.
[http://dx.doi.org/10.3390/ijms20051033] [PMID: 30818786]
[100]
Huang C-Y, Chen J-H, Tsai C-H, Kuo W-W, Liu J-Y, Chang Y-C. Regulation of extracellular signal-regulated protein kinase signaling in human osteosarcoma cells stimulated with nicotine. J Periodontal Res 2005; 40(2): 176-81.
[http://dx.doi.org/10.1111/j.1600-0765.2005.00788.x] [PMID: 15733153]
[101]
Yu D, An F, He X, Cao X. Curcumin inhibits the proliferation and invasion of human osteosarcoma cell line MG-63 by regulating miR-138. Int J Clin Exp Pathol 2015; 8(11): 14946-52.
[PMID: 26823826]
[102]
Maran A, Yaszemski MJ, Kohut A, Voronov A. Curcumin and osteosarcoma: Can invertible polymeric micelles help? Materials (Basel) 2016; 9(7): 520.
[http://dx.doi.org/10.3390/ma9070520] [PMID: 28773642]
[103]
Walters DK, Muff R, Langsam B, Born W, Fuchs B. Cytotoxic effects of curcumin on osteosarcoma cell lines. Invest New Drugs 2008; 26(4): 289-97.
[http://dx.doi.org/10.1007/s10637-007-9099-7] [PMID: 18071634]
[104]
Chapa-Oliver AM, Mejía-Teniente L. Capsaicin: From plants to a cancer-suppressing agent. Molecules 2016; 21(8): 931.
[http://dx.doi.org/10.3390/molecules21080931] [PMID: 27472308]
[105]
Wang Y, Deng X, Yu C, et al. Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts. J Exp Clin Cancer Res 2018; 37(1): 251.
[http://dx.doi.org/10.1186/s13046-018-0922-0] [PMID: 30326933]
[106]
Abe K, Yamamoto N, Hayashi K, Takeuchi A, Tsuchiya H. Caffeine citrate enhanced cisplatin antitumor effects in osteosarcoma and fibrosarcoma in vitro and in vivo. BMC Cancer 2019; 19(1): 689.
[http://dx.doi.org/10.1186/s12885-019-5891-y] [PMID: 31307409]
[107]
Reyes CM, Cornelis MC. Caffeine in the Diet: Country-level consumption and guidelines. Nutrients 2018; 10(11): 1772.
[http://dx.doi.org/10.3390/nu10111772] [PMID: 30445721]
[108]
Ma Y, Zhu B, Liu X, et al. Inhibition of oleandrin on the proliferation show and invasion of osteosarcoma cells in vitro by suppressing Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res 2015; 34(1): 115.
[http://dx.doi.org/10.1186/s13046-015-0232-8] [PMID: 26444270]
[109]
Yong L, Ma Y, Zhu B, et al. Oleandrin synergizes with cisplatin in human osteosarcoma cells by enhancing cell apoptosis through activation of the p38 MAPK signaling pathway. Cancer Chemother Pharmacol 2018; 82(6): 1009-20.
[http://dx.doi.org/10.1007/s00280-018-3692-7] [PMID: 30267330]
[110]
Yong L, Ma Y, Liang C, et al. Oleandrin sensitizes human osteosarcoma cells to cisplatin by preventing degradation of the copper transporter 1. Phytother Res 2019; 33(7): 1837-50.
[http://dx.doi.org/10.1002/ptr.6373] [PMID: 31050072]
[111]
Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002; 99(22): 14298-302.
[http://dx.doi.org/10.1073/pnas.162491399] [PMID: 12370430]
[112]
Ishida S, McCormick F, Smith-McCune K, Hanahan D. Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator. Cancer Cell 2010; 17(6): 574-83.
[http://dx.doi.org/10.1016/j.ccr.2010.04.011] [PMID: 20541702]
[113]
Sun S, Cai J, Yang Q, Zhao S, Wang Z. The association between copper transporters and the prognosis of cancer patients undergoing chemotherapy: A meta-analysis of literatures and datasets. Oncotarget 2017; 8(9): 16036-51.
[http://dx.doi.org/10.18632/oncotarget.13917] [PMID: 27980217]
[114]
Koski C, Sarkar N, Bose S. Cytotoxic and osteogenic effects of crocin and bicarbonate from calcium phosphates for potential chemopreventative and anti-inflammatory applications in vitro and in vivo. J Mater Chem B Mater Biol Med 2020; 8(10): 2048-62.
[http://dx.doi.org/10.1039/C9TB01462D] [PMID: 32064472]
[115]
Naghizadeh B, Boroushaki MT, Vahdati Mashhadian N, Mansouri MT. Protective effects of crocin against cisplatin-induced acute renal failure and oxidative stress in rats. Iran Biomed J 2008; 12(2): 93-100.
[PMID: 18506215]
[116]
Li X, Huang T, Jiang G, Gong W, Qian H, Zou C. Synergistic apoptotic effect of crocin and cisplatin on osteosarcoma cells via caspase induced apoptosis. Toxicol Lett 2013; 221(3): 197-204.
[http://dx.doi.org/10.1016/j.toxlet.2013.06.233] [PMID: 23830991]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 2
Year: 2021
Published on: 16 October, 2020
Page: [137 - 147]
Pages: 11
DOI: 10.2174/1573394716999201016160946
Price: $65

Article Metrics

PDF: 123
HTML: 2